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High mobility group box (HMGB)1 is a small
DNA-binding protein. In the nucleus, HMGB1 plays a
role in gene expression and DNA replication. When it
is released or secreted into the extracellular milieu,
HMGB1 functions as a pro-inflammatory cytokine-like
mediator. Recently reported data support the view
that treatment with a neutralizing anti-HMGB1
antibody ameliorated pulmonary damage in a murine
model of pneumonia caused by a pathogenic strain
of Staphylococcus aureus. These findings suggest that
HMGB1 may be an important drug target as scientists,
clinical investigators and pharmaceutical companies
seek to develop better agents for the treatment of
staphylococcal pneumonia. Unfortunately, however,
encouraging results from murine models of human
disease often fail to translate into positive findings in
clinical trials. Thus, before moving from pre-clinical
into clinical studies, it may be prudent to validate and
extend the recent experimental findings by carrying
out additional studies, using a large animal model of
pneumonia.cell types. Whether extracellular HMGB1 acts as a che-In a recent article in Critical Care, Achouiti and
co-workers [1] from the Academic Medical Center in
Amsterdam explored the role of high mobility group
box (HMGB)1 in an animal model of pneumonia caused
by a methicillin-resistant, highly pathogenic strain of
Staphylococcus aureus. In order to better understand the
implications of these findings, it is useful to briefly re-
view the ‘HMGB1 as inflammatory mediator’ story.
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2014histone DNA-binding protein. About 25 years later, Wang
and colleagues [3] identified HMGB1 as a late-acting me-
diator of lipopolysaccharide-induced lethality in mice.
This important paper opened up a fresh avenue of
research in immunology, one that led to the recognition
that certain endogenous molecules, which can be passively
released by stressed or necrotic cells or, in some cases,
actively secreted by immunostimulated macrophages and
certain other cell types, are capable of activating the innate
immune system and initiating or propagating inflamma-
tion. These molecules are now collectively referred to as
‘damage-associated molecular patterns’ (DAMPs). In
addition to HMGB1, other DAMPs include uric acid, heat
shock proteins, adenosine triphosphate, and partially
degraded forms of hyaluronic acid [4].
HMGB1 is a multifunctional protein. In the nucleus, it
participates in DNA replication and the regulation of
gene expression [5]. When it is released or secreted into
the extracellular milieu, HMGB1 can act as a chemokine
(that is, a chemoattractant for motile leukocytes) or a
cytokine (that is, an immune system mediator) to pro-
mote the secretion of other cytokines, such as tumor ne-
crosis factor, IL-1, and IL-6, by macrophages and other
mokine, cytokine or neither depends upon the redox
state of three critical cysteine residues (C23, C45 and
C106) in the protein [6,7]. In order for HMGB1 to func-
tion as a chemokine, the thiol moieties in all three of
these cysteine residues must exist in their fully reduced
form. In order to function as a cytokine, two of the
cysteine residues, C23 and C45, must form a disulfide
bond, whereas the third cysteine residue, C106, must
remain fully reduced. If the cysteine residues are fully
oxidized to the sulfonate form, then both the chemokine
and cytokine functions are abrogated. In its role as a
cytokine, HMGB1-dependent signaling is initiated pri-
marily by activation of Toll-like receptor (TLR)4 and the
receptor for advanced glycation endproducts (RAGE). In
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activation of the receptor CXCR4 [8].
Abundant evidence supports the view that HMGB1 is
an important pathological mediator in animal models of
several human diseases, including sepsis [9], hemorrhagic
shock [10], and acute respiratory distress syndrome
(ARDS) [11]. At present, ironclad evidence that HMGB1
is an important mediator of disease in humans is still
lacking, although elevated circulating levels of HMGB1
have been detected in patients with sepsis [12], ARDS [13]
or rheumatoid arthritis [14] and high levels of HMGB1
have been found in samples of synovial fluid from patients
with rheumatoid arthritis [15].
Achouiti and colleagues [1] employed a murine model
of sublethal pneumonia caused by a virulent strain of
methicillin-resistant S. aureus (MRSA). Using wild-type
mice as well as TLR4 and RAGE ‘knock-out’ (KO) mice,
Achouiti and colleagues showed that S. aureus pneumonia
was associated with HMGB1 release into bronchoalveolar
lavage fluid. Treatment with a neutralizing anti-HMGB1
antibody ameliorated pulmonary damage. RAGE KO mice
were partially protected from lung damage caused by
S. aureus pneumonia, whereas TLR4 KO mice were not
protected at all.
The data obtained by Achouiti and colleagues suggest
that HMGB1 might be a viable drug target in patients
with pneumonia caused by S. aureus, but the study
conducted by Achouiti and colleagues has some limita-
tions. First, the authors studied the role of HMGB1 in a
S. aureus pneumonia model in the absence of appropri-
ate antimicrobial chemotherapy. It is impossible to know
whether administration of an effective antibiotic would
have affected the results. Second, the mice were treated
with the neutralizing anti-HMGB1 antibody (or the con-
trol antibody) prior to the onset of infection. In the clin-
ical setting, treatment almost always would start after
the onset of infection. Third, concerns have been raised
about the predictive utility of murine models of sepsis
[16]. These concerns stem from recent data showing that
changes in gene expression in acutely endotoxemic mice
are quite distinct from those observed in acutely endotoxe-
mic human volunteers [17]. Furthermore, most studies
using mice are conducted with the animals maintained at
‘room temperature’ (20 to 23°C). Housing laboratory mice
under more physiological conditions (for the animals)
might lead to results that are more applicable to the clin-
ical situation [18]. Carrying out studies using a clinically
relevant large animal model of MRSA pneumonia, such as
the one described by Rehberg and colleagues [19], might
be another way to validate the findings obtained in mice.
Conclusion
Staphylococcal pneumonia is an important clinical prob-
lem [20,21]. There clearly is a pressing, unmet clinicalneed for improved therapeutics for staphylococcal
(particularly MRSA) pneumonia. Developing drugs that
target HMGB1 may be one way to tackle this problem,
although moving from the encouraging findings reported
by Achouiti and co-workers to the registration of a new
medicine will be an arduous task.
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